Form 4: Neurocrine Biosciences Director Leslie V. Norwalk Executes Stock Option and Sells Shares

Director Leslie V. Norwalk exercised stock options and sold 8,000 shares of Neurocrine Biosciences (NBIX) common stock on February 27, 2024, according to a Form 4 filing with the SEC.

Summary

• On February 27, 2024, Leslie V. Norwalk, a director of Neurocrine Biosciences Inc. (NBIX), exercised stock options to acquire 8,000 shares of common stock at a price of $84.95 per share.
• Simultaneously, Norwalk sold 8,000 shares of NBIX common stock at a weighted average price of $135.6735 per share, with individual sales prices ranging from $134.82 to $136.50.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 28, 2023.
• Following these transactions, Norwalk's direct ownership of NBIX common stock is reported as 0 shares, and the number of derivative securities beneficially owned following the reported transaction(s) is 1,724.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider trading activity. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about transactions.

Industry Context

This filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company directors. It is common for executives to utilize 10b5-1 trading plans to manage their stock holdings and avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider information being used for personal gain.

Key Dates